Filing Summary
Jazz Pharmaceuticals plc filed this Form 8-K on October 6, 2026, reporting a leadership transition. The report was signed on October 9, 2026.
Business Context and Reporting Period
This is a current report about an executive officer’s planned retirement, not a periodic financial report.
Financial Metrics and Comparisons
The filing provides no revenue, profit, cash flow, margin, debt, liquidity, or other financial results, and no comparable-period data.
Management Change and Outlook
Samantha Pearce, Executive Vice President and Chief Commercial Officer, notified the company of her intent to retire from the role upon the earlier of the appointment of her successor or June 30, 2027. Jazz plans to conduct a formal search considering internal and external candidates. The filing does not provide other guidance, financial outlook, or details about a successor.
Investor Items to Verify
- Whether a successor is appointed before June 30, 2027, and the effective transition date.
- Any subsequent disclosures about the search, transition arrangements, or changes to commercial leadership.